Jin Nakahara

Jin Nakahara

Auto-generated profile, based on publicly available information

Jin Nakahara

Department of Neurology Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet
Verified
Journal Article
Closed access
LKLudwig Kappos
Ludwig Kappos
ABAmit Bar-Or
Amit Bar-Or
BCBruce A C Cree
Bruce A C Cree
RFRobert J Fox
Robert J Fox
GGGavin Giovannoni
Gavin Giovannoni
Tjalf ZiemssenTjalf Ziemssen
Tjalf Ziemssen

4 May 2016 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
YWYurika Watanabe
Yurika Watanabe
AUAkinori Uruha
Akinori Uruha
SSShigeaki Suzuki
Shigeaki Suzuki
JNJin Nakahara
Jin Nakahara
KHKohei Hamanaka
Kohei Hamanaka
INIchizo Nishino
Ichizo Nishino
Objective To elucidate the common and distinct clinical features of immune-mediated necrotising myopathy (IMNM), also known as necrotising autoimmune myopathy associated with autoantibodies against signal recognition particle (SRP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). Methods We examined a cohort of 460 patients with idiopathic inflammatory myopathies (IIMs) through a muscle biopsy-oriented registration study in Japan. Study entry was strictly determined by the comprehensive histological assessment to exclude other neuromuscular disorders. Anti-SRP and anti-HMGCR antibodies were detected by RNA immunoprecipitation and ELISA, respectively. Results Of 460 patients with IIM, we diagnosed 73 (16%) as having inclusion body myositis (IBM). Of 387 patients with IIMs other than IBM, the frequencies of anti-SRP and anti-HMGCR antibodies were 18% and 12%, respectively. One patient had both autoantibodies. Severe limb muscle weakness, neck weakness, dysphagia, respiratory insufficiency and muscle atrophy were more frequently observed in patients with anti-SRP antibodies than in those with anti-HMGCR antibodies. Serum creatine levels were markedly higher in the patients with autoantibodies than in those without. Histology was characterised by necrosis and regeneration of muscle fibres and was consistent with IMNM except in 1 HMGCR-positive IBM patient. Most patients were initially treated with corticosteroids; however, additional immunosuppressive drugs were required, especially in the patients with anti-SRP antibodies. Rates of unsatisfactory neurological outcome were similar in the 2 autoantibody groups. Conclusions Anti-SRP antibodies are associated with severe neurological symptoms, more so than are anti-HMGCR antibodies. Although these autoantibodies are independent serological markers associated with IMNM, patients bearing either share common characteristics.

13 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SSShigeaki Suzuki
Shigeaki Suzuki
ANAtsuko Nishikawa
Atsuko Nishikawa
MKMasataka Kuwana
Masataka Kuwana
HNHiroaki Nishimura
Hiroaki Nishimura
YWYurika Watanabe
Yurika Watanabe
INIchizo Nishino
Ichizo Nishino
Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad. To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with anti-SRP antibody. We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP antibodies. Anti-SRP antibodies in serum were detected by the presence of 7S RNA using RNA immunoprecipitation. In addition, enzyme-linked immunosorbent assays (ELISAs) using a 54-kD protein of SRP (SRP54) and 3-hydroxyl-3-methylglutatyl-coenzyme A reductase (HMGCR) were also conducted. The mean onset age of the 61 female and 39 male patients was 51 years (range 4–82 years); duration ≥ 12 months before diagnosis was seen in 23 cases. All patients presented limbs weakness; 63 had severe weakness, 70 neck weakness, 41 dysphagia, and 66 muscle atrophy. Extramuscular symptoms and associated disorders were infrequent. Creatine kinase levels were mostly more than 1000 IU/L. Histological diagnosis showed 84 patients had necrotizing myopathy, and apparent cell infiltration was observed in 16 patients. Anti-SRP54 antibodies were undetectable in 18 serum samples with autoantibodies to 7S RNA. Anti-HMGCR antibodies were positive in 3 patients without the statin treatment, however, were negative in 5 patients with statin-exposure at disease onset. All but 3 patients were treated by corticosteroids and 62 (77 %) of these 81 patients required additional immunotherapy. After 2-years treatment, 22 (27 %) of these 81 patients had poor neurological outcomes with modified Rankin scale scores of 3–5. Multivariate analysis revealed that pediatric disease onset was associated with the poor outcomes. Anti-SRP antibodies are associated with different clinical courses and histological presentations.

1 June 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
SMSonoko Misawa
Sonoko Misawa
SKSatoshi Kuwabara
Satoshi Kuwabara
YSYasunori Sato
Yasunori Sato
NYNobuko Yamaguchi
Nobuko Yamaguchi
KNKengo Nagashima
Kengo Nagashima
HOH Ogata
H Ogata

1 August 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
ENEri Noguchi
Eri Noguchi
AUAkinori Uruha
Akinori Uruha
SSShigeaki Suzuki
Shigeaki Suzuki
KHKohei Hamanaka
Kohei Hamanaka
YOYuko Ohnuki
Yuko Ohnuki
INIchizo Nishino
Ichizo Nishino
Aminoacyl transfer RNA synthetase (ARS) is a cytoplasmic protein synthetase that catalyzes the binding of amino acids to their corresponding transfer RNA in an energy-dependent manner. Eight autoantibodies reacting with different ARSs have been recognized: anti-Jo-1 (histidyl), anti-PL-7 (threonyl), anti-PL-12 (alanyl), anti-EJ (glycyl), anti-OJ (isoleucyl), anti-KS (asparaginyl), anti-Zo (phenylalanyl), and anti-Ha (tyrosyl). Antisynthetase syndrome, characterized by myositis, interstitial lung disease, skin rash, arthropathy, and Raynaud phenomenon, is a clinical entity based on the presence of 1 of the ARS antibodies in patient’s serum.1 Because anti-Jo-1 antibodies are preferentially screened in patients with myositis, to our knowledge, muscle involvement of antisynthetase syndrome has not been fully elucidated.

22 December 2011 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
JNJin Nakahara
Jin Nakahara
MMMichiko Maeda
Michiko Maeda
SASadakazu Aiso
Sadakazu Aiso
NSNorihiro Suzuki
Norihiro Suzuki